Beijing Balance Medical Technology Co., Ltd. (688198.SH) had a net profit of 145 million yuan in 2024, an increase of 26.26% year-on-year.

Beijing Balance Medical Technology Co., Ltd. (688198.SH) released its 2024 annual performance report, stating that the company's product layout is increasingly optimized, strengthening market expansion and coverage based on product competitiveness, and continuously improving brand influence. The concept of full lifecycle management has become an industry consensus. While existing products showed stable growth, the contribution of newly launched products to revenue was prominent, boosting the company's profitability. The company achieved a total operating income of 503 million yuan for the year, a year-on-year increase of 35.67%, and a net profit attributable to the owners of the parent company of 145 million yuan, a year-on-year increase of 26.26%. Revenue from the company's three major business segments all saw year-on-year growth: the cardiac valve replacement and repair segment increased by 64.42%, with revenue from artificial biological heart valves up by 75.23%; the congenital heart disease intervention and surgical soft tissue repair segments saw year-on-year growth of 15.77% and 20.02%, respectively.